Ambrose Healthcare Ltd. is delighted to announce that it has won the Best Startup Biotech Company Award at the prestigious OBN Awards 2024, held on 20 November in London.
The OBN Awards acknowledge the most impactful life science companies, entrepreneurs, and innovations across the UK. The Best Startup Biotech Company category specifically recognizes the early-stage company making the most significant strides in transforming healthcare through scientific and business advancements.
“We are incredibly honored to win this OBN award,” said Georgia Wilson Waterworth, Co-founder and COO of Ambrose Healthcare. “At Ambrose Healthcare, we are seeking to drive change in the rare disease treatment landscape through rapidly progressing clinical development of in-licensed drug candidates and other solutions. The recognition from OBN Ltd reinforces Ambrose Healthcare's growing reputation as a leader in the rare disease space.”
Ambrose Healthcare’s most advanced drug candidate, within its late-stage portfolio, is a novel molecule being developed for gastrointestinal symptoms of cystic fibrosis. This is a growing quality of life challenge for these patients who are now living longer, for which there is no approved treatment.
Ambrose Healthcare is raising the last £500,000 of an EIS approved seed round to prepare for executing a potentially pivotal clinical study which, if successful, can be the basis for filing for regulatory approval utilizing rare disease regulations.
The award comes at an exciting time for Ambrose Healthcare, and follows last year’s success in winning National Life Sciences Startup of the Year 2023.
For more information, please contact: